Abemaciclib Improves Survival in Mets, HR+, HER2- BC

Options
Moderators
Moderators Member Posts: 25,912

Experimental Abemaciclib Improves Survival in Metastatic, Hormone-Receptor-Positive, HER2-Negative Breast Cancer
June 20, 2017

Experimental abemaciclib in combination with Faslodex offered better progression-free survival than Faslodex alone in women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer. Read more...

Categories